DONATE

Challenges and opportunities in biomedical research

The 15th Annual Conference of Biomedical Research Technology Platforms was held yesterday and, with more than 700 participants, it has become the reference forum for analyzing the main challenges and opportunities facing Spain in biomedical research. The event, which was attended by Josep Samitier, director of the Institute for Bioengineering of Catalonia (IBEC) and scientific coordinator of the Nanomed Spain platform, brought together representatives of the Administration, regulatory agencies, universities and companies, as well as clinical researchers and patients.

Mechanical signals involved in the early development of the mouse cerebral cortex described for the first time

A scientific team coordinated by José Antonio del Río from the Institute for Bioengineering of Catalonia (IBEC) observed the mechanical signals and traction forces involved in the migration of Cajal-Retzius cells, a group of neurons that play an important role in the development of the cerebral cortex. The study, conducted on rodents, has been published in the journal Frontiers in Cell and Developmental Biology.

Senior researcher at the Bioengineering in Reproductive Health Research Group


Application Deadline: 07/06/2022
Ref: SR-SO

The Bioengineering in Reproductive Health Group offers a position at the senior scientist or experienced postdoc level to develop a project within the framework of ATTRAC project (Horizon 2020 Research and Innovation Program) Prototyping a light-sheet microscope for the diagnostic of embryo implantation based on hyperspectral phasor analysis .
Our laboratory is a multidisciplinary environment where biologists, biophysicists, clinicians and business developers synergize to create a unique environment shaped by science and entrepreneurship. Due to the high translational component of our research, we have established collaboration contracts with the pharma industry, hospitals and venture capital to bring our technology to the clinics and the market.

In our lab we use bioengineering methods to create 3D environments that support embryonic development outside of the mother uterus. Our systems are accessible to imaging tools which allow us to interrogate the genetics, metabolomics and mechanics of the embryo in a high throughput manner. Using our systems we are capable to (i) improve embryo culture conditions and (ii) diagnose embryos with improved implantation potential.

Pau Gorostiza and cochlear implants in the media

Pau Gorostiza, principal investigator at IBEC and ICREA profesor, appears in the media for his study co-led with Tobias Moser, director of the Institute for Auditory Neuroscience. The study presents the first light-controlled drug that produces auditory stimulation in vivo without the need of genetic manipulation.

“Lessons and challenges after two years of pandemic” a FECYT report with IBEC collaboration

Yesterday, the report “Lessons and challenges after two years of pandemic” was presented at the Carlos III Health Institute in Madrid, the first in a series of studies on trends in Spanish research that the Spanish Foundation for Science and Technology (FECYT) will carry out each year and which will analyze current scientific issues.

IBEC´s Zaida Álvarez, Lorena Ruiz and Anna Seriola awarded at the third edition of the BIST “To the Mothers of Science” program

IBEC researchers Zaida Álvarez, Lorena Ruiz and Anna Seriola, along with 7 other scientists, have been declared winners of this third edition of the “To the Mothers of Science” program organized by the “Barcelona Institute of Science and Technology” (BIST) which aims to support outstanding female researchers on their pathway towards positions of greater responsibility.

The first light-controlled drug that could improve the hearing of people with cochlear implants

Researchers at the Institute for Bioengineering of Catalonia (IBEC) in Spain and the University Medical Center Göttingen in Germany achieve, for the first time, in vivo light-activated auditory stimulation without the need for genetic manipulation. This new light-controlled drug, capable of triggering the neural pathways involved in hearing, can contribute to improving the spectral resolution of cochlear implants used by people with profound hearing loss or deafness.